BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 16842213)

  • 1. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.
    Lage H
    Curr Drug Targets; 2006 Jul; 7(7):813-21. PubMed ID: 16842213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming multidrug resistance by RNA interference.
    Stege A; Krühn A; Lage H
    Methods Mol Biol; 2010; 596():447-65. PubMed ID: 19949936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.
    Stege A; Priebsch A; Nieth C; Lage H
    Cancer Gene Ther; 2004 Nov; 11(11):699-706. PubMed ID: 15375376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
    Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
    Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance.
    Lage H
    Recent Results Cancer Res; 2016; 209():87-94. PubMed ID: 28101689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
    Kaszubiak A; Holm PS; Lage H
    Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells.
    Chen BA; Mao PP; Cheng J; Gao F; Xia GH; Xu WL; Shen HL; Ding JH; Gao C; Sun Q; Chen WJ; Chen NN; Liu LJ; Li XM; Wang XM
    Int J Nanomedicine; 2010 Aug; 5():437-44. PubMed ID: 20957165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.
    Stein U; Walther W; Stege A; Kaszubiak A; Fichtner I; Lage H
    Mol Ther; 2008 Jan; 16(1):178-86. PubMed ID: 17878902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells.
    Chen XP; Wang Q; Guan J; Huang ZY; Zhang WG; Zhang BX
    World J Gastroenterol; 2006 Jun; 12(21):3332-7. PubMed ID: 16733848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial delivery of RNAi effectors: transkingdom RNAi.
    Lage H; Krühn A
    J Vis Exp; 2010 Aug; (42):. PubMed ID: 20811323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.
    Pan GD; Yang JQ; Yan LN; Chu GP; Liu Q; Xiao Y; Yuan L
    World J Gastroenterol; 2009 Jan; 15(4):431-40. PubMed ID: 19152447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites.
    Kobayashi H; Takemura Y; Wang FS; Oka T; Ohnuma T
    Int J Cancer; 1999 Jun; 81(6):944-50. PubMed ID: 10362143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
    Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
    Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance: molecular mechanisms and clinical relevance.
    Ling V
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
    Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
    Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
    Kobayashi H; Takemura Y; Miyachi H
    Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
    Abbasi M; Lavasanifar A; Uludag H
    Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.